Abstract:Accepted: April 9, 2023 ; Published: January 2024 Copyright: ©2024 Roster et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited. Funding: None. Competing interests: Dr. Lipner has served as a consultant for Hoth Therapeutics, Ortho Dermatologics, Moberg Pharmaceuticals, and Belle Torus Corporation. There are no conflicts of interest declared for the other authors. Authorship: All authors have contributed significantly to this publication. Keywords : Hidradenitis suppurativa, skin of color, healthcare utilization This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. References 1. Udechukwu, N. S., & Fleischer, A. B., Jr (2017). Higher Risk of Care for Hidradenitis Suppurativa in African American and Non-Hispanic Patients in the United States. Journal of the National Medical Association, 109(1), 44–48. https://doi.org/10.1016/j.jnma.2016.09.002 2. Khalsa, A., Liu, G., & Kirby, J. S. (2015). Increased utilization of emergency department and inpatient care by patients with hidradenitis suppurativa. Journal of the American Academy of Dermatology, 73(4), 609–614. https://doi.org/10.1016/j.jaad.2015.06.053 3. Robinson, I., Lee, L., & Cotton, C. (2022). The Impact of Racial Differences on Treatment Strategies in Hidradenitis Suppurativa: A Retrospective Review. Journal of drugs in dermatology : JDD, 21(3), 270–275. https://doi.org/10.36849/JDD.6446 4. Wehner, M. R., Micheletti, R., Noe, M. H., Linos, E., Margolis, D. J., & Naik, H. B. (2020). Hidradenitis suppurativa encounters in a national electronic health record database notable for low dermatology utilization, infrequent biologic prescriptions, and frequent opiate prescriptions. Journal of the American Academy of Dermatology, 82(5), 1239–1241. https://doi.org/10.1016/j.jaad.2019.12.030 5. Davis, S. A., Lin, H. C., Balkrishnan, R., & Feldman, S. R. (2015). Hidradenitis Suppurativa Management in the United States: An Analysis of the National Ambulatory Medical Care Survey and MarketScan Medicaid Databases. Skin appendage disorders, 1(2), 65–73. https://doi.org/10.1159/000431037

International time trends and differences in topical actinic keratosis therapy utilization

Association of Countries' Atopic Dermatitis Burden and Sociodemographic Index with Topical Calcineurin Inhibitor Utilization

Attitudes among dermatologists regarding actinic keratosis treatment options

Comparison of therapeutic agents' short‐term effects on facial and scalp actinic keratosis: A network meta‐analysis

The Prevalence of Actinic Keratosis in Patients Visiting Dermatologists in Two Hospitals in China.

Epidemiology and Risk Factors of Actinic Keratosis. What is New for The Management for Sun-Damaged Skin

Treatment of actinic keratosis: a systematic review

Clinical and Dermoscopic Comparison of the Efficacy and Safety of 5% Fluorouracil Topical Cream and 1% Niacinamide Topical Gel in the Treatment of Actinic Keratosis: A Randomized Controlled Trial

A Review of Existing Therapies for Actinic Keratosis: Current Status and Future Directions

Epidemiology, Treatment Patterns, and Healthcare Resource Utilization Study of Patients With Alopecia Areata in Taiwan's National Health Insurance Research Database

Regional differences in medical needs and care for skin cancer across Bavaria: confronting the gap

A Randomized, Double-blind, Vehicle-Controlled Study to Assess 5% Imiquimod Cream for the Treatment of Multiple Actinic Keratoses

The use of ingenol mebutate to treat actinic keratosis in standard clinical practice: a prospective phase IV multicenter observational cohort study

Developing a questionnaire for assessing clinician- and patient-reported outcomes in actinic keratosis: Results from an expert panel

The "Personalising Actinic Keratosis Treatment for Immunocompromised Patients" (IM-PAKT) Project: An Expert Panel Opinion

Actinic keratosis metrics

Actinic keratosis: Current challenges and unanswered questions

Topical Immunotherapy for Actinic Keratosis and Field Cancerization

Comparative Efficacy and Safety of Tirbanibulin for Actinic Keratosis of the Face and Scalp in Europe: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

Topical Pharmacotherapy for Actinic Keratoses in Older Adults

Specialty Utilization Disparities Among Hidradenitis Suppurativa Patients in a Retrospective Analysis of the National Ambulatory Medical Care Survey 2006-2016